Uncovering the effects and molecular mechanism of Astragalus membranaceus (Fisch.) Bunge and its bioactive ingredients formononetin and calycosin against colon cancer: An integrated approach based on network pharmacology analysis coupled with experimental validation and molecular docking

Yu Hu, Wenjuan Zhai, Duanling Tan, Haipeng Chen, Guiyu Zhang, Xuanjing Tan, Yuting Zheng, Wenhui Gao, Yijie Wei, Jinjun Wu, Xin YangFrontiers in Pharmacology 2023 · DOI

Abstract

Astragalus membranaceus (Huang Qi, HQ) is a staple in Traditional Chinese Medicine, often used to support colon cancer treatment. However, the specific molecular pathways it influences have remained unclear. This study employs an integrated approach—combining network pharmacology, experimental validation, and molecular docking—to investigate the anti-cancer effects of HQ and its primary isoflavonoids, formononetin (FMNT) and calycosin (CS). The findings reveal that these compounds significantly inhibit colon cancer cell proliferation and migration by targeting the ERK1/2 and PI3K-Akt signaling pathways, suggesting their potential as therapeutic supplements.

Introduction

Colon cancer is a leading cause of cancer-related mortality worldwide, characterized by poor prognosis and high recurrence. While HQ is clinically recognized for its therapeutic potential, identifying its active ingredients and their precise biological targets is essential for scientific validation. This research focuses on FMNT and CS to decode the "black box" of HQ's mechanism of action against colon malignancies, moving beyond traditional observation into high-resolution molecular mapping.

Methodology

The study utilized a three-tiered integrated approach:

  1. Network Pharmacology: Databases like TCMSP and GeneCards were mined to identify 147 overlapping targets between HQ's bioactive compounds and colon cancer. Protein-protein interaction (PPI) networks were constructed to identify hub genes.
  2. Experimental Validation: The effects of HQ extract, FMNT, and CS were tested on HT-29 and Caco2 human colon cancer cell lines. Assays included MTT and EdU for growth, flow cytometry for apoptosis, and Western blotting for protein expression (specifically p-ERK1/2 and p-Akt).
  3. Molecular Docking: Computational simulations predicted the physical binding affinity between FMNT/CS and key signaling proteins in the MAPK/ERK pathway, such as EGFR, BRAF, and MEK.

Results and Discussion

Network analysis identified 147 common targets, including major players like AKT1, TP53, and EGFR. Enrichment analysis highlighted the MAPK (ERK1/2) and PI3K-Akt pathways as the primary regulatory targets for FMNT and CS.

Enrichment analysis showing GO/KEGG pathways and the targeted ERK signaling cascade.

Experimental results showed that HQ, FMNT, and CS inhibited cell viability in a dose-dependent manner and significantly induced programmed cell death. Notably, the treatments suppressed the Epithelial-Mesenchymal Transition (EMT)—a key process in metastasis—by increasing E-cadherin and decreasing Vimentin expression, effectively "locking" cancer cells in place and reducing their migratory capacity.

Western blot analysis confirmed a striking reduction in phosphorylated ERK1/2 (the active form) levels without changing total protein amounts. Molecular docking further supported these findings, showing high binding affinities (lower than -7 kcal/mol) between the compounds and MAPK pathway kinases, suggesting they act as natural inhibitors of these growth-promoting enzymes.

Molecular docking simulations illustrating the binding of FMNT and CS to key protein targets.

Conclusion

This study demonstrates that Astragalus membranaceus and its components FMNT and CS exert potent anti-colon cancer effects by primarily inhibiting the ERK1/2 signaling pathway. While these in vitro and computational results are promising, the authors acknowledge the need for future in vivo studies to evaluate systemic efficacy and potential synergy with standard chemotherapies like 5-Fluorouracil. These findings provide a robust scientific basis for using HQ as a therapeutic supplement to enhance chemotherapeutic outcomes for colon cancer patients.

Summary updated

Abstract

Colon cancer is a highly malignant cancer with poor prognosis. <i>Astragalus membranaceus</i> (Fisch.) Bunge (Huang Qi in Chinese, HQ), a well-known Chinese herbal medicine and a popular food additive, possesses various biological functions and has been frequently used for clinical treatment of colon cancer. However, the underlying mechanism is not fully understood. Isoflavonoids, including formononetin (FMNT) and calycosin (CS), are the main bioactive ingredients isolated from HQ. Thus, this study aimed to explore the inhibitory effects and mechanism of HQ, FMNT and CS against colon cancer by using network pharmacology coupled with experimental validation and molecular docking. The network pharmacology analysis revealed that FMNT and CS exerted their anticarcinogenic actions against colon cancer by regulating multiple signaling molecules and pathways, including MAPK and PI3K-Akt signaling pathways. The experimental validation data showed that HQ, FMNT and CS significantly suppressed the viability and proliferation, and promoted the apoptosis in colon cancer Caco2 and HT-29 cells. HQ, FMNT and CS also markedly inhibited the migration of Caco2 and HT-29 cells, accompanied by a marked increase in E-cadherin expression, and a notable decrease in N-cadherin and Vimentin expression. In addition, HQ, FMNT and CS strikingly decreased the expression of ERK1/2 phosphorylation (p-ERK1/2) without marked change in total ERK1/2 expression. They also slightly downregulated the p-Akt expression without significant alteration in total Akt expression. Pearson correlation analysis showed a significant positive correlation between the inactivation of ERK1/2 signaling pathway and the HQ, FMNT and CS-induced suppression of colon cancer. The molecular docking results indicated that FMNT and CS had a strong binding affinity for the key molecules of ERK1/2 signaling pathway. Conclusively, HQ, FMNT and CS exerted good therapeutic effects against colon cancer by mainly inhibiting the ERK1/2 signaling pathway, suggesting that HQ, FMNT and CS could be useful supplements that may enhance chemotherapeutic outcomes and benefit colon cancer patients.
BibTeX
@inproceedings{hu2023uncovering,
  author = {Yu Hu and Wenjuan Zhai and Duanling Tan and Haipeng Chen and Guiyu Zhang and Xuanjing Tan and Yuting Zheng and Wenhui Gao and Yijie Wei and Jinjun Wu and Xin Yang},
  title = {{Uncovering the effects and molecular mechanism of Astragalus membranaceus (Fisch.) Bunge and its bioactive ingredients formononetin and calycosin against colon cancer: An integrated approach based on network pharmacology analysis coupled with experimental validation and molecular docking}},
  booktitle = {Frontiers in Pharmacology},
  year = {2023},
  doi = {10.3389/fphar.2023.1111912},
}
Figure